Immuron Ltd Owned Ateria Health Launches Juvia in Australia
Immuron Ltd Owned Ateria Health Launches Juvia in Australia
Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that Ateria Health Australia Pty Ltd, a subsidiary of Ateria Health Limited ("Ateria"), has launched Juvia in Australia.
澳大利亚证券交易所股票代码：IMC、纳斯达克代码：IMRN)今天欣然宣布，Ateria Health Limited(“Ateria”)的子公司Ateria Health Australia Pty Ltd在澳大利亚推出Juvia。
Immuron completed settlement of a strategic investment in Ateria on 16 November 2022 (17.5% shareholding). Ateria is a UK based biotech company that develops and distributes supplements for overall health, including products that strengthen the gut microbiome.
ImMuron于2022年11月16日完成了对Ateria的战略投资结算(持股17.5%)。Ateria是一家总部位于英国的生物技术公司，开发和分销针对整体健康的补充剂，包括增强肠道微生物群的产品。